Drug Discovery Services Market Overview
“The Drug Discovery Services Market is estimated to increase at a CAGR of 13.89% from $ 18.32 Billion in 2023 to $ 48.56 Billion by 2030.”
Drug Discovery Services is a new technical service offered to Cancer Centre Members, offering synthetic services of known chemicals or compounds of interest, saving money and providing non-commercially available chemicals. The four major phases of drug development are Early Drug Discovery, Pre-Clinical Phase, Clinical Phases, and Regulatory Approval, each involving primary steps.
Drug discovery requires significant resources and time, necessitating specialized skills across various scientific areas. Outsourcing these activities can save money and time for research institutes and pharmaceutical businesses. The market for outsourced medicine delivery services provides access to specialized infrastructure and knowledge without large expenditures. Pharmaceutical companies invest heavily in research and development (R&D) to deliver high-quality, innovative products to market. Top pharma businesses are increasing R&D efficiency through large spending to gain long-term benefits.
The Cancer Center Members are now offered a new technical service called Drug Discovery Services.
Service offerings include:
- Synthetic services are provided for known or potentially interesting substances, saving money and offering non-commercially available chemicals.
- Global chemical sourcing is a crucial method for sourcing chemical matter when time is of the essence.
- The aim is to increase the scale-up synthesis of chemicals of interest for more extensive research, including animal studies.
- The proposal is to offer a plate-format collection of chemicals from an in-house library, which can be utilized for phenotypic screening.
>>>Download Sample Report Now:https://marketreportservice.com/request-sample/drug-discovery-services-market-54530
Growth Drivers
- The demand for new drugs is on the rise to meet unmet medical needs.
- The goal is to enhance the cost-efficiency of the drug development process to increase its adoption.
The pharmaceutical and biopharmaceutical industries are increasingly focused on developing novel treatments for various diseases and disorders. Rising R&D spending and financing for research on rare and lifestyle illnesses have accelerated drug discovery processes, leading to outsourcing analytical testing and clinical trial services for regulatory clearance. Major pharmaceutical companies are also shifting towards outsourcing drug effectiveness and other attributes testing to avoid roadblocks and reduce the need for in-house personnel.
The biopharmaceutical industry is experiencing rapid growth due to increased government and corporate investments in developing new medications for chronic illnesses, favorable government laws, and active engagement from authorities like the FDA and EMA.
Restraint
The strict rules imposed by regulatory agencies on drug discovery services can hinder commercial advancements in the pharmaceutical sector. These regulations ensure safety, effectiveness, and quality, but they also increase the cost of medication discovery and development, leading to longer approval processes, higher development costs, and increased regulatory obstacles, which can stifle innovation and investment in drug research, particularly for small businesses.
Drug Discovery Services Market Segment Analysis
“Pharmaceutical companies hold a significant portion of the market share due to their extensive product and service offerings.”
Pharmaceutical corporations dominate the global market, accounting for 41.45% in 2022. They develop drug discovery strategies based on market trends and collaborate with research institutes and CROs to study specific diseases for specialized audiences. Increased spending on new medication discoveries and innovative drug introductions boost market growth.
“The process segment that currently holds the most dominance in Drug Discovery Services is the research process.”
The hit-to-lead identification approach dominates the market, identifying a hit compound through high-throughput screening. As technology advances and new facilities emerge, the lead optimization segment is expected to experience growing demand, as the traditional high-throughput screening method remains the norm.
“The type of drug discovery service with a significant market share is currently unknown.”
The medicinal chemistry services segment is predicted to grow at a double-digit CAGR, driven by pharmaceutical corporations outsourcing research and development services. This growth is driven by increased R&D spending and medication research and development activities. The biological services sector is also expected to experience rapid growth.
Competitive Landscape of the Drug Discovery Services Market Analysis
New Developments
Sep. 14, 2023, Charles River and Related Sciences Enter Multi-Program Collaboration to Pursue AI-Enabled Drug Discovery Utilizing Logica
Sep. 14, 2023-- Charles River Laboratories International, Inc. and Related Sciences (“RS”), a data science-driven drug discovery firm, today announced a multi-program collaboration agreement to apply Logica™ across several previously undrugged targets in the RS portfolio. Logica is an Artificial Intelligence (AI) powered drug solution that translates biological insights into optimized assets.
As a leader in drug discovery services, Eurofins Discovery launched its novel TPD service, E3scan™, in the middle of the COVID-19 pandemic. E3scan is based on previously established KINOMEscan® technology, which utilises a substrate-recruitment, site-directed competition binding assay. The platform now includes assays against 12 different E3 ligases, as well as individual substrate recognition domains for substrate selectivity determination. This platform is being constantly refined and expanded with additional assays ready for launch in late 2021 and in 2022.
Regional Analysis
Largest market-> North America
Fastest Growing Market-> Asia Pacific
In 2022, North America dominated the global drug discovery market, leading in research and development investment. The US has patented most innovative medications, and the growing demand for advanced treatments due to chronic illnesses has fueled market expansion.
With about half of the US population suffering from chronic illnesses, healthcare spending is substantial. Increased biologic awareness in the region also supports market growth.
The North America drug discovery market is expected to experience significant growth due to the increasing demand for generic pharmaceuticals, immunotherapy medications, and biosimilars.
The US market for popular medications like Remicade, Enbrel, Rituximab, Adalimumab, Infliximab, Etanercept, and Darbepoetin Alpha is expected to rapidly develop due to factors like regional healthcare spending and the introduction of innovative pharmaceutical technology.
Asia Pacific is expected to be the most promising market in the coming years due to the presence of multiple CROs, significant investment in the pharmaceutical sector by countries like South Korea, India, and China, and the growing senior population, who are more sensitive to chronic ailments. The United Nations predicts that by 2050, 80% of the world's elderly will live in poor and middle-income nations, resulting in a significant increase in drug discovery market growth.
In January 2023, Genentech declared that it received a Priority Review and Fast Track designation grant for Glofitamab. The drug is a novel bispecific antibody that engages T-cells of the immune system to treat adult patients with refractory or relapsed LBCL.
In January 2023, Brexpiprazole, an atypical antipsychotic supplement NDA approved for schizophrenia was put under Priority Review by FDA. Brexpiprazole is a drug developed by H. Lundbeck A/S and Otsuka Pharmaceuticals.
Segments Covered in the Drug Discovery Services Market Report
By Process
- Target Selection
- Target Validation
- Hit-to-Lead Identification
- Lead Optimization
- Candidate Validation
Type
- Chemistry Services
- Biological Services
Drug Type
- Small-molecule Drugs
- Large-molecule Drugs
Therapeutic Area
- Diabetes
- Neurology
- Oncology
- Infectious Diseases
- Other therapeutic areas
End-user
- Pharmaceutical & Biotechnology Companies
- Contract Research Organizations
- Other end-users
By Region
North America
Europe
- Germany
- UK
- France
- Spain
- Italy
- Poland
- Sweden
- Netherlands
Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Indonesia
- Philippines
- Vietnam
Latin America
- Brazil
- Mexico
- Argentina
- Columbia
- Peru
- Chile
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Turkey
- Israel
Frequently Asked Questions
What is the expected growth rate of the Drug Discovery Services market over the next 7 years?
Drug Discovery Services Market is estimated to increase at a CAGR of 13.89% from $ 18.32 Billion in 2023 to $ 48.56 Billion by 2030. | Report 2023 by published by Market Report Service.
Who are the major players in the Drug Discovery Services market and what is their market share?
Charles River Laboratories International Inc.,Thermo Fisher Scientific Inc.,Wuxi AppTec,Eurofins Scientific,America Holdings (US),Pharmaron Beijing Co., Ltd.,Piramal Enterprises Limited, are prominent players operating and dominating in the market.
Who are the top 3 Drug Discovery Services Market Key Vendors?
Charles River Laboratories International Inc.,Thermo Fisher Scientific Inc.,Wuxi AppTec, are key players in the Drug Discovery Services market.
Which geographical areas dominate the worldwide market for Drug Discovery Services?
North America region are emerging as the top regional markets for Drug Discovery Services solutions.
1.SUMMARY
1.1. Drug Discovery Services Market Overview
1.2. Key Insights
1.3. Report Scope
1.4. Research Methodology
1.5. Frequently Asked Questions
1.6. Chapter Outlines
- DECISION-MAKING SUMMARY
- INTRODUCTION
3.1. Overview of Drug Discovery Services
3.2. Key Historical Events
3.3. Structure
3.4. Biochemical Interaction
3.5. Target Indications
3.6. Advantages of Drug Discovery Services
3.7 Challenges associated with Drug Discovery Services
3.8. Future Perspectives.
- MARKET LANDSCAPE
4.1. Methodology
4.2 Drug Discovery Services: Developer Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters (Region-wise)
4.2.4. Analysis by Location of Headquarters (Country-wise)
4.2.5. Analysis by Year of Establishment, Company Size and Location of Headquarters (Region-wise)
4.2.6. Most Active Players
- COMPANY
5.1. Company Overview
5.1.2 Management Team
5.1.3. Product Portfolio
5.1.4. Recent Developments and Future Outlook
- PARTNERSHIPS AND COLLABORATIONS
6.1. Partnership Models
6.2. Drug Discovery Services: Partnerships and Collaborations
6.2.1. Analysis by Year of Partnership
6.2.2. Analysis by Type of Partnership
6.2.3. Analysis by Year and Type of Partnership
6.2.4. Analysis by Type of Partner
6.2.5. Analysis by Year of Partnership and Type of Partner
6.2.6. Analysis by Type of Partnership and Type of Partner
6.2.7. Analysis by Type of Partner and Parent Company Size
- ACADEMIC GRANTS ANALYSIS
7.1. Methodology and Key Parameters
7.2. Drug Discovery Services: Academic Grants Analysis
7.2.1. Analysis by Year of Grant Award
7.2.2. Analysis by Amount Awarded
7.2.3. Analysis by Funding Institute Center
7.2.4. Analysis by Support Period
7.2.5. Analysis by Funding Institute Center and Support Period
7.2.6. Analysis by Type of Grant Application
7.2.7. Analysis by Purpose of Grant
- PUBLICATION ANALYSIS
8.1. Analysis Methodology and Key Parameters
8.2. Drug Discovery Services: Publication Analysis
8.2.1. Analysis by Year of Publication
8.2.2. Analysis by Type of Publication
8.2.3. Analysis by Type of Conjugate
8.2.4. Analysis by Target Indication
8.2.5. Analysis by Copyright Holder
8.2.6. Word Cloud: Emerging Focus Area
8.2.7. Most Active Publishers: Analysis by Number of Publications
- SUCCESS PROTOCOL ANALYSIS
9.1. Methodology and Key Parameters
9.2. Key Assumptions and Scoring Criteria
9.3. Success Protocol Analysis
9.4. Assessment of Approved Drug Discovery Services
- Appendix 1: Tabulated Data
- Appendix 2: List of Companies
- Charles River Laboratories International Inc.
- Thermo Fisher Scientific Inc.
- Wuxi AppTec
- Eurofins Scientific
- America Holdings (US)
- Pharmaron Beijing Co., Ltd.
- Piramal Enterprises Limited
